Strides Pharma Science has reported total income of Rs.921.54 crores during the period ended March 31, 2021 as compared to Rs.845.22 crores during the period ended December 31, 2020. The company has reported total income of s.636.29 crores during the period ended March 31, 2020.

The company has posted net profit of Rs.46.08 crores for the period ended March 31, 2021 as against net profit of Rs.37.84 crores for the period ended December 31, 2020. The company has posted net loss of Rs.(203.92) crores for the period ended March 31, 2020. 

Strides Pharma Science has reported total income of Rs.3367.29 crores during the 12 months period ended March 31, 2021 as compared to Rs.2805.08 crores during the 12 months period ended March 31, 2020.

Strides Pharma Science has posted net profit of Rs.268.44 crores for the 12 months period ended March 31, 2021 as against net profit f Rs.36.39 crores for the 12 months period ended March 31, 2020.

Commenting on the performance, Dr R Ananthanarayanan, Managing Director & CEO, remarked, "Amidst a tough operating environment, we are pleased to have delivered a healthy performance across all businesses in FY21. Our regulated markets franchise which now contributes 80% of revenues has seen significant ramp up in FY21 growing 21% YoY inline with our outlook. The emerging markets business witnessed a strong bounce back in FY21 benefitting from launch of TLD albeit at lower gross margins.

Our revenue during the year has grown 29% YoY to ₹33,308m with an EBITDA growth of 67% to ₹6,497m. EBITDA margin for FY21 was at 19.5%, a healthy expansion of 450bps YoY despite a significant cost increase of ₹1,293m from logistics and Failure to Supply largely owing to COVID-19 related disruptions.

While in the near term we are witnessing operational challenges owing to a rampant second wave of COVID19 in India, we believe we have all the strategic pivots in place to continue on our growth momentum and deliver strong financial outcomes for our stakeholders over the next 3 years."